PF-00610355 – an inhaled β2 adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
LAS100977, a novel β2 -agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
The bronchodilator effects of the novel anti-inflammatory compound TPI 1020, alone and in combination with formoterol, in conscious guinea pigs Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Potency and duration of action of R,R-glycopyrrolate (RRG) on acetylcholine (ACh) induced bronchoconstriction as compared to tiotropium (TIO) in unrestrained conscious mice Source: Eur Respir J 2005; 26: Suppl. 49, 217s Year: 2005
Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Does the inhalation device affect the bronchodilatory dose response curve of Salbutamol in asthma- and COPD patients? Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
NVA237 has similar efficacy as tiotropium bromide against methacholine-induced bronchoconstriction and less systemic effect on cardiovascular variables in an anaesthetized rabbit model Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006
Use of multifactor-dimensionality reduction model predicting bronchodilator response by inhaled short-acting beta 2 agonist Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Protective effect of budesonide/formoterol in a model of repeated exposure to inhaled adenosine 5‘-monophosphate (AMP) in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 353s Year: 2007
CHF6366: characterisation of the bronchoprotective effect of a novel MABA compound in the experimental bronchospasm model in anaesthetised guinea pigs Source: International Congress 2017 – Novel studies on bronchodilators and cough Year: 2017
Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol Source: Eur Respir J 2001; 17: 368-373 Year: 2001
RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016